GeNeuro SA of Geneva, Switzerland has made an initial public offering of €33 million on the Euronext stock exchange in Paris. Part of the proceeds will be used to finance a Phase 2b proof-of-concept trial of an antibody for multiple sclerosis (MS). ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
